As Onyx Details Come Out, Amgen Turns To Biosimilars
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen is juggling both ends of its strategy, one focused on biosimilars and the other on new R&D-driven products. Further details have emerged about each, as Amgen tries to make the case it's a revenue growth story.